GEERT CAUWENBERGH Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GEERT CAUWENBERGH.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GEERT CAUWENBERGH. GEERT CAUWENBERGH is Chief Executive Officer in BARRIER THERAPEUTICS INC ($BTRX) and Chief Executive Officer in Phio Pharmaceuticals Corp. ($RXII) and Director in Phio Pharmaceuticals Corp. ($PHIO) and President & CEO in RXi Pharmaceuticals Corp ($RXII).
Latest Insider Trading Transactions of GEERT CAUWENBERGH
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 03 2021 | PHIO | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Director | Grant | A | 0.00 | 10,000 | 0 | 22,822 | 12.8 K to 22.8 K (+77.99 %) |
| Nov 20 2019 | PHIO | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Director | Grant | A | 0.10 | 225,000 | 22,500 | 704,841 | 479.8 K to 704.8 K (+46.89 %) |
| Aug 02 2019 | PHIO | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Director | Payment of Exercise | F | 0.40 | 1,751 | 706 | 479,841 | 481.6 K to 479.8 K (-0.36 %) |
| Mar 01 2019 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.38 | 152,415 | 57,887 | 481,592 | 329.2 K to 481.6 K (+46.30 %) |
| Feb 19 2019 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.36 | 22,279 | 8,096 | 329,177 | 306.9 K to 329.2 K (+7.26 %) |
| Feb 04 2019 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.38 | 21,470 | 8,096 | 306,898 | 285.4 K to 306.9 K (+7.52 %) |
| Jan 22 2019 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.34 | 23,729 | 8,096 | 285,428 | 261.7 K to 285.4 K (+9.07 %) |
| Jan 07 2019 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.35 | 23,139 | 8,096 | 261,699 | 238.6 K to 261.7 K (+9.70 %) |
| Dec 26 2018 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.30 | 27,445 | 8,096 | 238,560 | 211.1 K to 238.6 K (+13.00 %) |
| Dec 10 2018 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.37 | 21,882 | 8,096 | 211,115 | 189.2 K to 211.1 K (+11.56 %) |
| Nov 26 2018 | RXII | Phio Pharmaceutica ... | CAUWENBERGH GEERT | Chief Executive Off ... | Grant | A | 0.31 | 25,941 | 8,096 | 189,233 | 163.3 K to 189.2 K (+15.89 %) |
| Nov 13 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.43 | 18,698 | 8,096 | 163,292 | 144.6 K to 163.3 K (+12.93 %) |
| Oct 29 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.44 | 18,519 | 8,097 | 144,594 | 126.1 K to 144.6 K (+14.69 %) |
| Oct 15 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.47 | 17,230 | 8,096 | 126,075 | 108.8 K to 126.1 K (+15.83 %) |
| Oct 01 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 1.17 | 73,587 | 86,097 | 108,845 | 35.3 K to 108.8 K (+208.71 %) |
| Aug 03 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 1.79 | 21,000 | 37,590 | 21,000 | |
| Aug 03 2018 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.00 | 21,000 | 0 | 35,258 | 14.3 K to 35.3 K (+147.29 %) |
| Oct 02 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.45 | 7,100 | 3,195 | 142,583 | 135.5 K to 142.6 K (+5.24 %) |
| Oct 02 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.46 | 200 | 92 | 135,483 | 135.3 K to 135.5 K (+0.15 %) |
| Oct 02 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.44 | 2,700 | 1,188 | 135,283 | 132.6 K to 135.3 K (+2.04 %) |
| Aug 24 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.56 | 739 | 414 | 132,583 | 131.8 K to 132.6 K (+0.56 %) |
| Aug 24 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.55 | 4,361 | 2,399 | 131,844 | 127.5 K to 131.8 K (+3.42 %) |
| Aug 24 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.55 | 4,900 | 2,671 | 127,483 | 122.6 K to 127.5 K (+4.00 %) |
| Jun 22 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.62 | 5,000 | 3,100 | 122,583 | 117.6 K to 122.6 K (+4.25 %) |
| Jun 22 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.63 | 5,000 | 3,150 | 117,583 | 112.6 K to 117.6 K (+4.44 %) |
| Apr 26 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.65 | 10,000 | 6,480 | 112,583 | 102.6 K to 112.6 K (+9.75 %) |
| Mar 20 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.77 | 15 | 11 | 102,583 | 102.6 K to 102.6 K (+0.01 %) |
| Mar 20 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.77 | 665 | 509 | 102,568 | 101.9 K to 102.6 K (+0.65 %) |
| Mar 20 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.77 | 9,320 | 7,172 | 101,903 | 92.6 K to 101.9 K (+10.07 %) |
| Feb 21 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.70 | 2,917 | 2,027 | 92,583 | 89.7 K to 92.6 K (+3.25 %) |
| Feb 21 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 6,883 | 4,766 | 89,666 | 82.8 K to 89.7 K (+8.31 %) |
| Feb 21 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 200 | 138 | 82,783 | 82.6 K to 82.8 K (+0.24 %) |
| Feb 08 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 10,000 | 6,850 | 82,583 | 72.6 K to 82.6 K (+13.78 %) |
| Feb 03 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.63 | 13,000 | 8,177 | 13,000 | |
| Jan 26 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.70 | 9,700 | 6,759 | 72,583 | 62.9 K to 72.6 K (+15.43 %) |
| Jan 26 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 300 | 207 | 62,883 | 62.6 K to 62.9 K (+0.48 %) |
| Jan 19 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 600 | 417 | 62,583 | 62 K to 62.6 K (+0.97 %) |
| Jan 19 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.69 | 3,000 | 2,084 | 61,983 | 59 K to 62 K (+5.09 %) |
| Jan 19 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.70 | 6,400 | 4,448 | 58,983 | 52.6 K to 59 K (+12.17 %) |
| Jan 03 2017 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.73 | 2,000 | 1,452 | 52,583 | 50.6 K to 52.6 K (+3.95 %) |
| Dec 27 2016 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.72 | 3,000 | 2,157 | 4,500 | 1.5 K to 4.5 K (+200.00 %) |
| Dec 23 2016 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.75 | 3,000 | 2,247 | 53,583 | 50.6 K to 53.6 K (+5.93 %) |
| Dec 20 2016 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.90 | 33,333 | 30,000 | 33,333 | |
| Dec 20 2016 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.90 | 33,333 | 30,000 | 50,583 | 17.3 K to 50.6 K (+193.23 %) |
| Feb 12 2016 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.29 | 133,000 | 38,011 | 133,000 | |
| Jun 23 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | X | 0.46 | 35,000 | 15,925 | 0 | |
| Jun 23 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | X | 0.46 | 35,000 | 15,925 | 172,500 | 137.5 K to 172.5 K (+25.45 %) |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.52 | 5,000 | 2,600 | 5,000 | |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.46 | 5,000 | 2,275 | 5,000 | |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.52 | 35,000 | 18,200 | 35,000 | |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.46 | 35,000 | 15,925 | 35,000 | |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.40 | 10,000 | 4,000 | 15,000 | 5 K to 15 K (+200.00 %) |
| Jun 03 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Grant | A | 0.40 | 70,000 | 28,000 | 137,500 | 67.5 K to 137.5 K (+103.70 %) |
| Jun 02 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Option Exercise | A | 0.38 | 133,000 | 50,540 | 133,000 | |
| Apr 02 2015 | RXII | RXi Pharmaceutical ... | CAUWENBERGH GEERT | President & CEO | Buy | P | 0.72 | 5,000 | 3,596 | 67,500 | 62.5 K to 67.5 K (+8.00 %) |
| Aug 10 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 5.44 | 1,000 | 5,437 | 11,000 | 10 K to 11 K (+10.00 %) |
| Aug 10 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 5.44 | 600 | 3,262 | 518,867 | 518.3 K to 518.9 K (+0.12 %) |
| Aug 10 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 5.42 | 400 | 2,168 | 518,267 | 517.9 K to 518.3 K (+0.08 %) |
| May 19 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 6.17 | 4,000 | 24,680 | 8,000 | 4 K to 8 K (+100.00 %) |
| May 19 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 6.17 | 1,000 | 6,166 | 516,560 | 515.6 K to 516.6 K (+0.19 %) |
| Apr 04 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Option Exercise | A | 9.68 | 25,000 | 242,000 | 25,000 | |
| Mar 15 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 9.25 | 1,300 | 12,022 | 515,560 | 514.3 K to 515.6 K (+0.25 %) |
| Mar 15 2006 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 9.25 | 700 | 6,475 | 514,260 | 513.6 K to 514.3 K (+0.14 %) |
| Apr 04 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Option Exercise | A | 15.52 | 25,000 | 388,000 | 25,000 | |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Option Exercise | M | 3.50 | 2,970 | 10,395 | 2,970 | |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.47 | 200 | 2,894 | 4,000 | 3.8 K to 4 K (+5.26 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.34 | 1,300 | 18,642 | 3,800 | 2.5 K to 3.8 K (+52.00 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.80 | 100 | 1,480 | 511,288 | 511.2 K to 511.3 K (+0.02 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.79 | 100 | 1,479 | 511,188 | 511.1 K to 511.2 K (+0.02 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.78 | 100 | 1,478 | 511,088 | 511 K to 511.1 K (+0.02 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 14.77 | 1,200 | 17,724 | 510,988 | 509.8 K to 511 K (+0.24 %) |
| Mar 14 2005 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | M | 3.50 | 2,970 | 10,395 | 509,788 | 506.8 K to 509.8 K (+0.59 %) |
| Aug 16 2004 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 10.70 | 1,500 | 16,050 | 2,500 | 1,000 to 2.5 K (+150.00 %) |
| Aug 16 2004 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 10.16 | 1,000 | 10,160 | 505,318 | 504.3 K to 505.3 K (+0.20 %) |
| May 06 2004 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 15.00 | 1,000 | 15,000 | 1,000 | 0 to 1,000 |
| May 06 2004 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 15.00 | 1,000 | 15,000 | 1,000 | 0 to 1,000 |
| May 06 2004 | BTRX | BARRIER THERAPEUTI ... | CAUWENBERGH GEERT | Chief Executive Off ... | Buy | P | 15.00 | 1,000 | 15,000 | 1,000 | 0 to 1,000 |
Page: 1